Interest of Eosinopia in the Diagnosis of Infection in the Emergency Department

Eosinopenia Clinical Trial

— SEPSISEO  

Official title:

Interest of Eosinopia in the Diagnosis of Infection in the Emergency Department

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03467672
• Other study ID #: 6228
• Status: Recruiting
• Start date: March 23, 2018
• Est. completion date: March 2020

Study information

• Verified date: April 2019
• Source: University Hospital, Strasbourg, France
• Contact: Charles-Eric Dr. LAVOIGNET
• Phone: 03 84 98 33 97
• Email: Charles-eric.lavoignet[@]hnfc.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Several studies have described the interest of eosinopenia as a marker of infection in internal medicine or in intensive care units. Eosinopenia is an inexpensive and easily accessible biological marker of sepsis. Retrospective work in the adult emergency departments of Strasbourg University Hospitals has shown the good specificity of this biological sign for the diagnosis of infection. Our work aims to confirm the results by a more meaningful study.

Main objective: Evaluation of the interest of eosinopenia in the diagnosis of bacterial infection in ED.

Methodology: inclusion of all patients with criteria for bacterial infection in ED, inclusion of an equivalent number of uninfected control patients.

Duration : 12 months Multicentric prospective study 6 centers : Strasbourg, Hôpital Nord Franche comté, Sélestat, Wissembourg, Colmar, Mulhouse

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2000
• Est. completion date: March 2020
• Est. primary completion date: March 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• major patient

• patient suspected of infection and benefiting from the routine practice of NFS, whatever the indication during his / her visit to the emergency room.

• patient with or without criteria for bacterial infection

• patient affiliated to a social security scheme

• patient (or legal representative) who has agreed to participate in the study

Exclusion Criteria:

• anti tumor chemotherapy

• immunosuppressive treatment

• corticotherapy

• antibiotherapy in progress

• malignant hemopathy

• evolutionary cancer

• refusal to participate in the study

• subjects under safeguard of justice

• subject under guardianship or curatorship

Related Conditions & MeSH terms

• Emergencies
• Eosinopenia

Intervention

Other:
• Diagnosis of bacterial infection
use of eosinopenia in the diagnosis of bacterial infection

Locations

Country	Name	City	State
France	CH de COLMAR	Colmar
France	CH de MULHOUSE	Mulhouse
France	Ch Selestat	Sélestat
France	Les Hôpitaux Universitaires de Strasbourg	Strasbourg
France	CH Nord Franche comte	Trévenans
France	Ch Wissembourg	Wissembourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	eosinopenia as a sepsis marker	Evaluation of the interest of eosinopenia in the diagnosis of infectious states in emergencies.	102 month